Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBIT Margin (2016 - 2025)

Macrogenics (MGNX) has disclosed EBIT Margin for 14 consecutive years, with 29.34% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 10275.0% to 29.34% in Q4 2025 year-over-year; TTM through Dec 2025 was 48.72%, a 16229.0% increase, with the full-year FY2025 number at 48.72%, up 2501.0% from a year prior.
  • EBIT Margin was 29.34% for Q4 2025 at Macrogenics, down from 25.59% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 25.59% in Q3 2025 to a low of 1763.06% in Q2 2024.
  • A 5-year average of 329.89% and a median of 303.85% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: plummeted -142078bps in 2024, then skyrocketed 159779bps in 2025.
  • Macrogenics' EBIT Margin stood at 411.65% in 2021, then soared by 104bps to 16.39% in 2022, then crashed by -2908bps to 460.39% in 2023, then skyrocketed by 71bps to 132.1% in 2024, then soared by 78bps to 29.34% in 2025.
  • Per Business Quant, the three most recent readings for MGNX's EBIT Margin are 29.34% (Q4 2025), 25.59% (Q3 2025), and 165.27% (Q2 2025).